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This study aims to evaluate the change in gait spatiotemporal parameters in subjects with Parkinson’s disease (PD) before and
after Automated Mechanical Peripheral Stimulation (AMPS) treatment. Thirty-five subjects with PD and 35 healthy age-matched
subjects took part in this study. A dedicatedmedical device (Gondola) was used to administer the AMPS. All patients with PDwere
treated in off levodopa phase and their gait performances were evaluated by an inertial measurement system before and after the
intervention. The one-way ANOVA for repeated measures was performed to assess the differences between pre- and post-AMPS
and the one-way ANOVA to assess the differences between PD patients and the control group. Spearman’s correlations assessed the
associations between patients with PD clinical status (H&Y) and the percentage of improvement of the gait variables after AMPS
(𝛼 < 0.05 for all tests). The PD group had an improvement of 14.85% in the stride length; 14.77% in the gait velocity; and 29.91% in
the gait propulsion.The correlation results showed that the higher the H&Y classification, the higher the stride length percentage of
improvement.The treatment based on AMPS intervention seems to induce a better performance in the gait pattern of PD patients,
mainly in intermediate and advanced stages of the condition.
1. Introduction
1
2
3
4
The most typical gait pattern of Parkinson’s disease (PD) is
a short-stepped shuffling gait. It is characterized by reduced
stride length and walking speed [1, 2]. These gait disorders
worsen progressively, as the disease advances, and are related
to the risk of falling among the Parkinsonians [3].Therefore,
5 it is not surprising that gait impairment in PD is the major
contributor to decreased patients’ quality of life [4].
The management of PD was traditionally centered on
drug therapy, with levodopa being its “gold standard” treat-
ment [5]. Several studies have demonstrated the ability of
levodopa to decrease stride length and improve walk speed
[6]. However, as the disease progresses, chronic levodopa
treatment can be associated with response decrease and with
development of motor complications, including wearing-off
episodes and dyskinesia [5].
To reduce thesemotor fluctuations, new treatments based
onperipheral stimulation of the sensory-motor system, called
bottom-up stimulation, have been inspiring new rehabili-
tation approaches in PD [7, 8]. Recently, new approaches
have been developed to recover the gait impairment such as
the Automated Mechanical Peripheral Stimulation (AMPS)
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Figure 1: The device used for the AMPS treatment: 1 (a) the specific points of feet stimulation; (b) the two moving steel bars; (c) patient
positioning.
treatment [9, 10]. The AMPS is delivered by a dedicated
device, known asGondola (Ecker Technologies, Switzerland),
and consists in the application of a pressure via rounded
stimulation tips in the four areas to be stimulated (two in each
foot, which are the head of the big toe and the first metatarsal
joint).6
Stocchi et al. [9] evaluated the change in gait and the
clinical status of 18 patients with PD after 6 sessions of a
treatment based on AMPS. The study results indicate that
the AMPS treatment has positive effect on bradykinesia and
allows the improvement of walking velocity. Furthermore,
AMPS has a positive effect on the step and stride length and
on walking stability, measured as the increase in stride length
and the reduction of double support time during walk.These
results are consistent, and the results of improvement were
measured via clinical scales.
Also recently, Galli et al. [10] evaluated a group of PD
patients before and after AMPS evaluated with the Timed
Up and Go (TUG) test, a widely used clinical performance-
basedmeasure of fall risk,measuredwith inertial sensors.The
AMPS treatment improves the walking stability and seems to
reduce the risk of falls in patients with PD. After the AMPS
patients performed the TUG test faster and improved some
kinematic parameters as the velocity to stand up from a chair
and to sit down.
Based on these findings, the current study aims to evalu-
ate the impact of the AMPS in functional abilities, measured
with gait spatiotemporal parameters based on a single inertial
wearable sensor. Recently, wireless inertial sensing devices
are being developed also for the assessment of spatial-
temporal parameters in unobstructed environment outdoors,
thus overcoming the typical limitations of measurements
in indoor laboratory settings. Several applications in the
rehabilitation and recovery of patient mobility have been
already reported by using these devices [11–14], more specific
in patients with PD [5, 15–17].
The aim of this study was to assess and to quantify if7
theAMPS is capable of promoting changes on spatiotemporal
parameters of PD gait. More specifically, this paper aims
to assess the associations of the patients’ clinical status
with the percentage of improvement of the gait variables
(stride length, velocity, cadence, and propulsion) after AMPS.
Table 1: Anthropometric characteristics.
Variables Parkinson Control group 𝑃
Age (years) 68.15 ± 6.83 66.27 ± 6 0.419
Body mass (kg) 74.8 ± 12.54 73.22 ± 11.45 0.147
Height (cm) 162.73 ± 13.04 164.81 ± 10.10 0.315
H&Y 3.27 ± 1.09 — —
UPDRS III 30.1 ± 10.4 — —
Disease duration
(years) 10.2 ± 6.3 — —
The hypothesis of this study is that the AMPS stimulation
improves the spatiotemporal gait of patients with PD, and the
more compromised the patient is, the more benefits he/she
will have after the bottom-up rehabilitation. 8
2. Methods
2.1. Participants. The Parkinson group (PD) consisted in 35
patients affected by Parkinson’s disease. PD was diagnosed
based on clinical criteria [18, 19], dopamine transporter (DaT)
scans, and/or magnetic resonance imaging. All these patients
are similar in terms of disease duration and are free of
peripheral sensory neuropathy and other disorders based on
their reported histories, symptoms, physical examinations,
and clinical tests. Patients with liver, kidney, lung, or heart
diseases, diabetes, or other causes of autonomic dysfunction
were not included in the study.
The characteristics of the considered subjects are sum-
marized in Table 1. The control group (CG) consisted in 35
healthy adults with the average characteristics in Table 1. 9
The study has been approved by the Ethics Research
Committee of the IRCCS San Raffaele Institute. The trial was
registered online at ClinicalTrials.gov ( identifier number 10
NCT01815281). All procedures were explained to the partic-
ipants and were carried out with their adequate understand-
ing, after receiving their written informed consent.
2.2. Experimental Procedures. During all intervention PD
patients were in off phase, after an overnight withdrawal of 11
all anti-Parkinsonian treatments.
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Figure 2: Significance and standard deviation of gait spatiotemporal parameters before and after AMPS: (a) stride length; (b) velocity; and
(c) propulsion. ∙ = 𝑃 < 0.05 between pre- and post-AMPS; + = 𝑃 < 0.05 between PD and control group.
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Figure 3: Correlation observed between the PD clinical status
(H&Y) and the stride length percentage of improvement (stride
length %) after AMPS.
2.2.1. The Automated Mechanical Peripheral Stimulation
(AMPS). The treatment consists in the application of a pres-
sure via rounded stimulation tips in four specific target areas
in patient’s feet (Figure 1(a)). To perform this mechanical
stimulation, a dedicated medical device (Gondola, Gondola
Medical Technologies, Lugano, Switzerland) was used to
deliver the AMPS (Figure 1(b)). The system consists of feet
supports (left and right) with electrical motors which activate
two actuated steel bars with a 2 mm diameter; the motor-
activated stimulators apply a mechanical pressure in two
specific areas of each foot: on the head of the hallux, left and
right, and on the 1st metatarsal joint, left and right.
Before treatment, the device needs to be adjusted to the
patient’s feet (Figure 1(c)): an inner sole of the correct size
is inserted in each unit (left and right) to accommodate the
feet; then the feet are inserted in the two units and tied up,
using three straps per foot; after that, correct length steel bars
are mounted on the axis of the electrical motors. The next
step consists in positioning the motors that are mounted on
adjustable platforms in order to make the steel bars interact
with the areas to be stimulated (head of the hallux and first
metatarsal joint of both feet). Once the device is adjusted,
the excursion of the four motors (which work independently
from each other) is programmed (using a remote control),
aiming to apply the correct pressure stimulation on each area.
The pressure of stimulation, always applied in a range of
0.3–0.9N/mm2, is set for each subject upon appearance of
themonosynaptic reflex in the Tibialis Anteriormuscle by the
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detection of a liminaris contraction while applying pressure
in the contact areas.12
Once the pressure value has been set using this procedure,
the value is recorded to administer the AMPS. This prepara-
tory procedure requires approximately 10 minutes.13
The treatment consists in 4 cycles; one cycle includes
a stimulation of the 4 target areas requiring 24 seconds,
whereas the overall 4-cycle treatment lasts for a total of 96
seconds. During the AMPS treatment, patients lay down
(Figure 1(d)). At the end of the AMPS stimulation, both units
of the device are removed from the feet of the patient; this
final action is very easy and fast (less than 1 minute). This14
link shows images of a pre- and post-AMPS patient’s gait
(http://youtu.be/deHFpt5gk3A).
2.2.2. The Inertial Sensor. The single inertial sensor is a wire-
less inertial sensing device (GSensor, BTS Bioengineering
S.p.A., Italy) which provides acceleration along three orthog-
onal axes: anteroposterior, mediolateral, and superoinferior.
Acceleration data were transmitted via Bluetooth to a PC
and processed using dedicated software (BTS G-STUDIO,
version: 2.6.12.0).
The portable GSensor consists in a wireless network of
inertial sensors for human movement analysis. The sensors
are controlled by a data logger unit (up to 16 elements),
a ZigBee radio type communication. Each sensor is sized
62mm × 36mm × 16mm, weighs 60 g, and is composed of
a 3-axis accelerometer (max range ± 6 g), a 3-axis gyroscope
(full scale ± 300∘/s), and a 3-axis magnetometer (full scale ± 6
gauss).This sensing device is calibrated with the gravitational
acceleration immediately after its manufacturing process.
Only one sensor was used during this work. It was attached
to the subjects’ waists with a semielastic belt, covering the L4-
L5 intervertebral space, in a way acceleration was collected
about the three orthogonal anatomical axes, that is, the
anterior-posterior, mediolateral, and vertical axes.15
The reference coordinate frame had the 𝑧-axis oriented
to the front, 𝑥-axis oriented vertically upward, and 𝑦-
axis orthogonal to the other two, towards the right. This
motion analysis was performed with a sensitivity for the
F4A accelerometer of 3G and a sampling frequency of 50Hz.
Acceleration data were transmitted via Bluetooth to a PC
and processed with the use of dedicated software (BTS G-
STUDIO, version: 2.6.12.0), which automatically provides the
parameters described next.
All study participants were asked to walk at a self-selected
speed along a pathway. Then, from the collected acceleration
signals, the following typical spatial-temporal gait parameters
were obtained:
(i) Stride length [m], the distance between two consecu-
tive heel strikes of the same foot.
(ii) Stride length/height [%], the stride length normalized
by subject height.
(iii) Speed [cm/s], the average instantaneous speed within
the gait cycle as integration of acceleration.
(iv) Cadence [strides/min], the number of strides in a
minute.
(v) Propulsion [m/s2], the anterior-posterior acceleration
peak during the lower limb swing phase.
2.3. Statistical Analysis. For statistical analysis, the data were
first tested for normality with the Kolmogorov-Smirnov
test. Because all the behavioral data exhibited normal dis-
tributions, parametric statistics were applied. The one-way
ANOVAs (𝛼 < 0.05) were applied to compare the anthro-
pometric data (i.e., age, body mass, and height) between the
PD group and the CG. Furthermore, this test was applied
to compare the differences between the right and the left
lower limbs of the PD group and the CG. Once no significant
differences were found between the right and left limbs, the
left limb was selected to represent the CG and PD bodies for
all gait variables comparisons.
Then, the described parameters were computed for each
participant and for each trial, and significant values and stan-
dard deviations of all indexes were calculated for each group.
After verifying that the parameters were normally distributed
bymeans of Kolmogorov-Smirnov test, the one-way ANOVA
for repeated measures (𝛼 < 0.05) was performed to assess the
differences between pre- and post-AMPS; also, the one-way
ANOVA for independentmeasures (𝛼 < 0.05)was performed
to assess the differences between PD before and after AMPS 16
and control group.
17Next, Spearman’s correlations (𝛼 < 0.05) were used to
assess the associations between the Hoehn & Yahr (H&Y)
[20] patient with PD clinical status and the percentage of
improvement of the gait variables (stride length, velocity,
cadence, and propulsion) after AMPS. The interpretation of
the correlation degree is as follows: 0.9 to 1 indicated a very
high correlation; 0.7 to 0.9 indicated a high correlation; 0.5
to 0.7 indicated a moderate correlation; 0.3 to 0.5 indicated a
low correlation; and 0 to 0.3 indicated little to no correlation.
All tests were two tailed. SPSS (version 19, IBM, Armonk,
New York, United States) was used to perform all statistical
analyses.
3. Results
Figure 2 illustrates the spatiotemporal gait parameters results
before and after AMPS. The patients with PD post-AMPS
treatment presented longer stride length (Figure 2(a)); 18
higher gait velocity (Figure 2(b)); and higher propulsion
(Figure 2(c)).
For the 35 PDpatients evaluated 57.14%H&Y stage 4; 20%
H&Y stage 3; 5.71% H&Y stage 2, 5; 8.57% H&Y stage 1, 5;
and 8.57% H&Y stage 1 . Figure 3 illustrates a significant and 19
high positive correlation observed between the clinical status
of the PD patients (H&Y) and the stride length percentage of
improvement after AMPS (𝜌 = 0.733; 𝑃 = 0.013). The more
compromised the PDpatient, the higher the percentage of the
stride length improvement after AMPS intervention.
4. Discussion
The aim of this study was to evaluate the effect of AMPS
treatment in PD subjects using a single inertial sensor to
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quantify the gait spatiotemporal parameters. Supporting our
hypothesis, this study’s results indicated that the AMPS
stimulation improves the spatiotemporal gait parameters
(stride length, walking velocity, and propulsion) of patients
with PD and showed high correlation between the patient
clinical status (H&Y) and the stride length percentage of
improvement after AMPS.
Before AMPS, the spatiotemporal data acquired by a
single inertial sensor were in accordance with previous
studies [5], and the PD patients in the off stage of levodopa
presented lower stride length and slower walking than the
aged matched control groups.20
Notwithstanding remaining in the “off medication” state,
after one intervention with AMPS the PD group had an
improvement of 14.85% in the stride length; 14.77% in the
gait velocity; and 29.91% in the gait propulsion. The AMPS
treatment seems to generate a more stable walking pattern in
PD patients, reducing the well-known gait impairment that is
typical of Parkinson’s disease, mainly in off stages. Stocchi et
al. [9] and Galli et al. [10] support these findings.
Moreover, the results of this study give a new insight of the
AMPS as an effective therapy for thewell-being of PDpatients
that helps improving their dynamic balance, especially in
compromised clinical status patients. The correlation results
show that the more severe the impairment of the PD patient,
the higher the percentage of stride length improvement
induced by the AMPS intervention.
The study has some limitations. The relatively small
number of participants studied resulted in limited strength
of the statistical findings. However, it documents the use of
a new approach for the PD patient rehabilitation: the AMPS
treatment applied via dedicated portable device.
5. Conclusion
The treatment based on AMPS induces a better performance
in the gait pattern of PD patients. The obtained results
showed that the AMPS treatment represents a promising
rehabilitation. The results indicated that PD patients may
be potential beneficiaries of the AMPS treatment once they
face many neuromotor deficits, mainly in intermediate and
advanced stages of the disease.These results are in agreement
with our previous study done by a multifactorial quantitative
laboratory. Moreover, the wearable devices are able to detect
the typical motor fluctuations of PD patients after off lev-
odopa and to document and quantify improvements follow-
ing rehabilitation techniques such as the AMPS treatment.
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